GOP Strategist Asks Republicans To Challenge Joe Biden On Drug Pricing: 'Go After It'

Strategists are formulating counter-messages for Republicans against President Joe Biden‘s plan to negotiate Medicare drug prices, arguing that it could stifle innovation and lead to price controls, Politico reported.

The GOP’s reframing of the drug pricing debate comes as Democrats plan to make it a key campaign issue in the upcoming election.

"Republicans have to figure out how to go after it. They go after it by taking it head on: it is killing clinical programs, fundamentally restricting the amount of treatments," said Joe Grogan, a Republican strategist and former domestic policy adviser for former President Donald Trump.

Grogan added that the negotiation process could potentially stifle innovation by pressuring drug manufacturers to accept a final negotiated rate or exit Medicare and Medicaid, which could account for up to 40% of their total revenue.

See Also: Bernie Sanders Speaks Out Against Potential Democratic Primary, Underscores Threat Posed By Trump: ‘He’s…A Very, Very Dangerous Person

A recent poll from the nonprofit KFF revealed that 58% of independent voters trust Democrats over Republicans (39%) to lower drug costs.

However, the GOP has yet to present a clear alternative to the Democrats’ plan.

Read Next: Runway debris is causing $4 billion in damages to the aviation industry every year. One startup funded by the US Department of Defense and Homeland Security aims to solve this nuisance in a spectacular fashion and you can invest in it today. Click here to see how.

Image by Unsplash/ Volodymyr Hryshchenko


Engineered by Benzinga Neuro, Edited by Pooja Rajkumari


The GPT-4 Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.


Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CareMediaGeneralDonald TrumpGOPJoe BidenMedicare price negotiationsmedicine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!